JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Replimune Group (NASDAQ:REPL) Stock

Replimune Group (NASDAQ:REPL) had its price objective upped by analysts at JPMorgan Chase & Co. from $16.00 to $18.00 in a report issued on Wednesday,Benzinga reports. The firm currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price indicates a potential upside of 32.77% from the stock’s current price.

A number of other brokerages have also recently issued reports on REPL. Jefferies Financial Group boosted their target price on shares of Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, December 4th. HC Wainwright raised their target price on Replimune Group from $21.00 to $22.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. Finally, BMO Capital Markets lifted their price objective on shares of Replimune Group from $18.00 to $27.00 and gave the company an “outperform” rating in a research note on Wednesday, January 22nd. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $19.43.

Replimune Group Trading Up 0.5 %

Shares of NASDAQ REPL traded up $0.07 during mid-day trading on Wednesday, hitting $13.56. The company’s stock had a trading volume of 135,685 shares, compared to its average volume of 718,737. Replimune Group has a one year low of $4.92 and a one year high of $17.00. The company has a debt-to-equity ratio of 0.14, a current ratio of 11.43 and a quick ratio of 11.43. The stock has a market cap of $1.04 billion, a price-to-earnings ratio of -4.43 and a beta of 1.30. The company’s fifty day simple moving average is $12.74 and its 200-day simple moving average is $11.95.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings data on Wednesday, February 12th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.09). On average, sell-side analysts anticipate that Replimune Group will post -2.97 earnings per share for the current fiscal year.

Insider Transactions at Replimune Group

In other news, CEO Sushil Patel sold 10,000 shares of the company’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $12.42, for a total value of $124,200.00. Following the completion of the transaction, the chief executive officer now directly owns 202,014 shares in the company, valued at approximately $2,509,013.88. This represents a 4.72 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 8.80% of the stock is owned by corporate insiders.

Institutional Trading of Replimune Group

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Baker BROS. Advisors LP boosted its holdings in shares of Replimune Group by 10.0% during the 3rd quarter. Baker BROS. Advisors LP now owns 11,045,336 shares of the company’s stock valued at $121,057,000 after buying an additional 1,000,000 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in shares of Replimune Group by 11.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 10,962,883 shares of the company’s stock valued at $132,761,000 after purchasing an additional 1,083,633 shares in the last quarter. Redmile Group LLC grew its position in Replimune Group by 2.6% in the fourth quarter. Redmile Group LLC now owns 4,905,527 shares of the company’s stock worth $59,406,000 after acquiring an additional 124,344 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Replimune Group by 3.7% during the 4th quarter. Vanguard Group Inc. now owns 3,595,848 shares of the company’s stock worth $43,546,000 after purchasing an additional 129,601 shares during the period. Finally, Braidwell LP boosted its holdings in shares of Replimune Group by 203.0% in the third quarter. Braidwell LP now owns 3,070,837 shares of the company’s stock valued at $33,656,000 after purchasing an additional 2,057,460 shares during the period. Institutional investors own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.